These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 14631401)

  • 1. New thoughts on the immunology of corneal transplantation.
    Streilein JW
    Eye (Lond); 2003 Nov; 17(8):943-8. PubMed ID: 14631401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2176-85. PubMed ID: 7558710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber.
    Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2833-43. PubMed ID: 9418737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 May; 38(6):1130-8. PubMed ID: 9152232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune privilege and immunogenicity reside among different layers of the mouse cornea.
    Hori J; Joyce NC; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3032-42. PubMed ID: 10967061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior chamber-associated immune deviation promotes corneal allograft survival.
    Niederkorn JY; Mellon J
    Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2700-7. PubMed ID: 8977485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.
    Niederkorn JY; Mayhew E; Mellon J; Hegde S
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2674-81. PubMed ID: 15277491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latanoprost does not affect immune privilege of corneal allografts.
    Wang M; Kitahara Y; Yoshida A; Hori J
    Exp Eye Res; 2008 Feb; 86(2):394-402. PubMed ID: 18187130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule.
    Hori J; Joyce N; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):443-52. PubMed ID: 10670474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.
    Streilein JW; Bradley D; Sano Y; Sonoda Y
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):413-24. PubMed ID: 8603847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenic privilege of corneal allografts.
    Niederkorn JY; Peeler JS; Ross J; Callanan D
    Reg Immunol; 1989; 2(2):117-24. PubMed ID: 2701814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye.
    Streilein JW
    Eye (Lond); 1995; 9 ( Pt 2)():236-40. PubMed ID: 7556724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal transplantation--immunologically privileged status.
    Katami M
    Eye (Lond); 1991; 5 ( Pt 5)():528-48. PubMed ID: 1794420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Implantation of FK506 drug delivery system into the anterior chamber for inhibiting corneal rejection in high risk rabbit corneal allograft].
    Shi WY; Liu T; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):299-304. PubMed ID: 16762204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanisms of corneal graft failure in the rat.
    Katami M
    Eye (Lond); 1995; 9 ( Pt 2)():197-207. PubMed ID: 7556718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved method for examining the corneal endothelium during graft rejection in the rat.
    Figueiredo FC; Pendergrast DG; Zhang L; Easty DL; Nicholls SM
    Exp Eye Res; 1998 Dec; 67(6):625-30. PubMed ID: 9990327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditions affecting enhanced corneal allograft survival by oral immunization.
    Ma D; Mellon J; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1835-46. PubMed ID: 9727406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection.
    Amescua G; Collings F; Sidani A; Bonfield TL; Rodriguez JP; Galor A; Medina C; Yang X; Perez VL
    Transplantation; 2008 Feb; 85(4):615-25. PubMed ID: 18347542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in leukocyte phenotype and interferon-gamma expression in stroma and endothelium during corneal graft rejection.
    Nicholls SM; Banerjee S; Figueiredo FC; Crome S; Mistry S; Easty DL; Dick AD
    Exp Eye Res; 2006 Aug; 83(2):339-47. PubMed ID: 16616741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment.
    Dua HS; Azuara-Blanco A
    Indian J Ophthalmol; 1999 Mar; 47(1):3-9. PubMed ID: 16130277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.